-
Taltirelin Acetate: Practical Research Workflows
2026-08-20
Taltirelin acetate connects TRHR1-focused neuromodulation with practical Parkinson’s disease, itch, sleep, and formulation workflows. This guide translates its preclinical use into controlled dosing, dissolution testing, assay selection, and troubleshooting strategies.
-
ELP-Mediated p21 Delivery in Glioblastoma
2026-08-20
The reference study shows that p21-ELP1-Bac, a p21-derived inhibitory peptide transported by an elastin-like polypeptide and cell-penetrating peptide, suppresses proliferation across three glioblastoma models. Its predominantly cytostatic activity, sustained intracellular localization, and cell-line-dependent tolerance support further evaluation of ELP-based intracellular delivery strategies.
-
Cy3-UTP for RNA Nanostructure QC
2026-08-19
Cy3-UTP adds a practical fluorescence-based quality-control layer to in vitro transcription RNA labeling and RNA nanostructure studies. This article explains how to use Cy3 signal to interpret structure, delivery, and assay performance without confusing fluorescence with functional RNA silencing.
-
Caspase-4 Colorimetric Assay Kit Workflow
2026-08-19
Use the Caspase-4 Colorimetric Assay Kit to quantify LEVD-dependent enzymatic activity in inflammation and pyroptosis experiments, rather than relying only on endpoint morphology. This workflow connects substrate cleavage data with organelle-targeted cancer-cell studies while clearly separating validated assay readouts from exploratory mechanistic hypotheses.
-
MTT Assays for Translational Chemoradiation Research
2026-08-18
A mechanistic and translational guide to using MTT as a metabolic readout when evaluating targeted, radiation-activated chemotherapy platforms.
-
Selonsertib (GS-4997) in Metabolic Stress Assays
2026-08-18
Selonsertib (GS-4997) enables selective ASK1 pathway interrogation in oxidative stress, inflammation, fibrosis, and diabetic kidney disease models. This workflow-focused guide shows how to connect ASK1 inhibition with autophagy, steatosis, and metabolic-stress readouts while avoiding common interpretation and formulation errors.
-
SCH772984 for Reliable ERK1/2 Assays
2026-08-17
Learn how SCH772984 (SKU A3805) can improve experimental control in ERK1/2-dependent cell viability, proliferation, and cytotoxicity assays. This scenario-based guide covers mechanism, dosing, DMSO stock preparation, pathway readouts, model selection, and practical supplier evaluation.
-
Injectable Hydrogel for Safer Tumor Ablation
2026-08-17
The reference study introduces MR@CaP@HA, an injectable hydrogel that combines local thermal insulation with pH/GSH-responsive delivery of mitoxantrone and Resiquimod (R-848) during radiofrequency ablation. In animal models, this integrated chemo-immunomodulatory approach protected adjacent tissues, strengthened post-ablation immune activity, and produced complete tumor eradication in a subset of treated animals.
-
CGF Reprograms CRC Metabolism to Trigger Cancer Cell Death
2026-08-16
Jiang et al. identify Cya-Gly-Fer (CGF), a natural anthocyanin derivative from purple sweet potato, as a preclinical colorectal cancer inhibitor that connects ABC transporter disruption with ATP accumulation, mitochondrial dysfunction, ROS overload, and suppression of the MAPK/ERK1/2/c-MYC axis. The study’s integrated cell, organoid, xenograft, transcriptomic, and metabolomic design provides a framework for linking metabolic stress to cell-cycle arrest and apoptosis while also evaluating preliminary safety and pharmacokinetic behavior.
-
EGCG Workflows for Antiangiogenic Research
2026-08-15
Build reproducible EGCG experiments for apoptosis, endothelial-cell inhibition, inflammation, and cancer chemoprevention. This guide translates an anti-inflammatory airway-stent study into practical screening, release-testing, and troubleshooting workflows without overstating what the reference study demonstrated.
-
AZD8055: Practical mTOR Inhibitor Workflow
2026-08-14
AZD8055 is an ATP-competitive mTOR inhibitor for controlled studies of mTORC1 and mTORC2 signaling, cancer-cell proliferation, and metabolic responses. It is suited to mechanistic preclinical workflows, but its poor aqueous solubility, limited clinical benefit, and lack of directly matched paper evidence require careful formulation and independent validation.
-
Nitroaromatic Nannocystin Targets AKT1 in CRC
2026-08-14
A 2024 study developed a synthetically accessible nitroaromatic nannocystin and showed that compound 4 suppresses colorectal cancer models from cell culture to patient-derived xenografts. Integrated transcriptomics, molecular docking, and cellular thermal shift analysis implicated AKT1 as part of the compound’s mechanism, while apoptosis, cell-cycle disruption, and senescence provided complementary phenotypic evidence.
-
One-step TUNEL Cy3 Apoptosis Detection Kit
2026-08-13
The One-step TUNEL Cy3 Apoptosis Detection Kit provides a direct readout of apoptotic DNA fragmentation in glioblastoma and other models. This article explains how to use the assay to connect mitochondrial stress, ribosome-associated quality control, and cell-death phenotypes without overinterpreting TUNEL positivity.
-
Resiniferatoxin: A Translational TRPV1 Strategy
2026-08-13
Resiniferatoxin (RTX) offers a distinctive route to durable TRPV1-positive sensory neuron silencing, but its translational value depends on more than potency. This thought-leadership perspective connects RTX mechanism, model selection, immune-context findings, and route-specific development strategy.
-
Mithramycin A Workflows for Gene Regulation
2026-08-12
Mithramycin A combines G-C-rich DNA binding with transcriptional suppression, creating a practical perturbation tool for leukemia research and mechanistic cancer biology research. This guide connects its established c-myc and HL-60 applications with a carefully bounded workflow for investigating the miR-24-3p/Sp1/PI3K axis in cardiac injury models.